Imperial College London
Portrait Picture

MissKerlannLe Calvez

Faculty of Medicine, Department of Surgery & Cancer

Honorary Research Officer
 
 
 
//

Contact

 

+44 (0)20 3311 5307k.le-calvez

 
 
//

Location

 

Charing Cross HospitalCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Chen:2022:10.1016/j.radonc.2022.02.011,
author = {Chen, J and Sinclair, G and Rozati, H and Hill, L and Pakzad-Shahabi, L and Wang, J and Calvez, KL and Paddick, I and Williams, M},
doi = {10.1016/j.radonc.2022.02.011},
journal = {Radiotherapy and Oncology},
pages = {176--183},
title = {Improving on whole-brain radiotherapy in patients with large brain metastases: a planning study to support the AROMA clinical trial},
url = {http://dx.doi.org/10.1016/j.radonc.2022.02.011},
volume = {170},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - PURPOSE: To develop a novel dose-escalated volumetric modulated arc therapy (VMAT) strategy for patients with single or multiple large brain metastases which can deliver a higher dose to individual lesions for better local control (LC), and to compare dosimetry between whole brain radiotherapy (WBRT), hippocampal-sparing whole brain radiotherapy (HS-WBRT) and different VMAT-based focal radiotherapy approaches. METHODS AND MATERIALS: We identified 20 patients with one to ten brain metastases and at least one lesion larger than 15 cm3 who had received WBRT as part of routine care. For each patient, we designed and evaluated five radiotherapy treatment plans, including WBRT, HS-WBRT and three VMAT dosing models. A dose of 20 Gy in 5 fractions was prescribed to the whole brain or target volumes depending on the plan, with higher doses to smaller lesions and dose-escalated inner planning target volumes (DE-iPTV) in VMAT plans, respectively. Treatment plans were evaluated using the efficiency index, mean dose and D0.1cc to the target volumes and organs at risk. RESULTS: Compared with WBRT, VMAT plans achieved a significantly more efficient dose distribution in brain lesions, especially with our DE-iPTV model, while minimising the dose to the normal brain and other organs at risks (OARs) (p < 0.05). CONCLUSIONS: VMAT plans obtained higher doses to brain metastases and minimised doses to OARs. Dose-escalated VMAT for larger lesions allows higher radiotherapy doses to be delivered to larger lesions while maintaining safe doses to OARs.
AU  - Chen,J
AU  - Sinclair,G
AU  - Rozati,H
AU  - Hill,L
AU  - Pakzad-Shahabi,L
AU  - Wang,J
AU  - Calvez,KL
AU  - Paddick,I
AU  - Williams,M
DO  - 10.1016/j.radonc.2022.02.011
EP  - 183
PY  - 2022///
SN  - 0167-8140
SP  - 176
TI  - Improving on whole-brain radiotherapy in patients with large brain metastases: a planning study to support the AROMA clinical trial
T2  - Radiotherapy and Oncology
UR  - http://dx.doi.org/10.1016/j.radonc.2022.02.011
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35182688
UR  - https://www.sciencedirect.com/science/article/pii/S0167814022000962?via%3Dihub
UR  - http://hdl.handle.net/10044/1/95758
VL  - 170
ER  -
Download